Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study

A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder

NCT07204314 ·Status: RECRUITING ·Phase: PHASE3

Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)

NCT00610649 ·Status: COMPLETED ·Phase: PHASE2

Safety and Antidepressant Effects of Rellidep in Major Depressive Disorder

NCT00446719 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder

NCT01491035 ·Status: COMPLETED ·Phase: PHASE2

Controlled Study to Evaluate the Safety and Efficacy of the Predictix Antidepressant Clinician Support Tool

NCT04031157 ·Status: UNKNOWN ·Phase: NA

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy

NCT04951609 ·Status: TERMINATED ·Phase: PHASE1

Safety of REL-1017 for Major Depressive Disorder

NCT04855760 ·Status: COMPLETED ·Phase: PHASE3

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)

NCT00035009 ·Status: COMPLETED ·Phase: PHASE3

A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)

NCT05081167 ·Status: COMPLETED ·Phase: PHASE3

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)

NCT00035295 ·Status: COMPLETED ·Phase: PHASE3

BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder

NCT03193398 ·Status: COMPLETED ·Phase: PHASE2

A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)

NCT04688164 ·Status: COMPLETED ·Phase: PHASE3

Effects of Antidepressants on Sexual Functioning

NCT00051259 ·Status: COMPLETED ·Phase: PHASE3

Evaluating the Role of the Microbiome in Antidepressant Treatment in Adolescents.

NCT06633497 ·Status: NOT_YET_RECRUITING

Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder

NCT01198795 ·Status: COMPLETED ·Phase: PHASE4

Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study

NCT01152996 ·Status: COMPLETED ·Phase: PHASE3

Pharmacogenetic-Guided Antidepressant Prescribing in Adolescents With Anxiety and Depression

NCT06853587 ·Status: RECRUITING ·Phase: NA

Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder

NCT01355081 ·Status: COMPLETED ·Phase: PHASE3

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)

NCT00034944 ·Status: COMPLETED ·Phase: PHASE3

Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression

NCT03766867 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder

NCT01255787 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

NCT01163266 ·Status: COMPLETED ·Phase: PHASE3

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)

NCT00034983 ·Status: COMPLETED ·Phase: PHASE3

Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

NCT00694304 ·Status: COMPLETED ·Phase: PHASE3

Investigate Efficacy & Safety of RO4995819 vs. Placebo as Adjunct Tx in Patients w/Major Depressive Disorder

NCT01733654 ·Status: WITHDRAWN ·Phase: PHASE2